Precision targeting of MET in NSCLC: A multidisciplinary approach
55:13
Precision targeting of MET in NSCLC: A multidisciplinary approach
39:16
Where to next in limited-stage small cell lung cancer? The role of immune checkpoint inhibitors
33:48
Primary biliary cholangitis: Appraising the changing therapeutic landscape
31:53
Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease
51:31
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
32:03
Vaccination strategies for pneumococcal disease: Update and perspectives on clinical need and impact
40:57
Expanding HER2 horizons: Implications for NSCLC and beyond
30:44